CAMBER CAPITAL MANAGEMENT LP
Q1 2025 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001444043
· CRD 298070
· SEC-registered investment adviser
$2.8B Reported Value Total
CAMBER CAPITAL MANAGEMENT LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $3,681,457,704, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $3.6B gross asset value
Hedge Fund: $3.6B
Source: Form ADV filed 2025-04-09
Reported value
$2.8B
Quarter over quarter
-0.9%
Holdings
28
Top-10 concentration
78.3%
Key People
Form ADV owners & control persons
Stephen Rodney Dubois
MANAGING MEMBER
Brian James Foley
CHIEF OPERATING OFFICER
Sean George
CHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 15, 2025 |
| Form | 13F-HR |
| Reported value | $2.8B |
| Positions | 28 |
| Change in reported value | -34.9% |
| New positions | 1 |
| Exited positions | 9 |
| Position turnover | 27.0% |
| Top-10 concentration | 78.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2025 13F
Filed Aug 14, 2025
|
23 | $1.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
28 | $2.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
36 | $4.3B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
32 | $3.1B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $3.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
34 | $4.1B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
36 | $3.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
39 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
38 | $3.1B |
|
Q1 2023 13F
Filed May 15, 2023
|
40 | $3.3B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
38 | $2.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
42 | $3.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
40 | $2.3B |
|
Q1 2022 13F
Filed May 16, 2022
|
37 | $2.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
36 | $2.9B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
34 | $3.2B |
|
Q2 2021 13F
Filed Aug 16, 2021
|
30 | $3.0B |
|
Q1 2021 13F
Filed May 17, 2021
|
31 | $2.9B |
|
Q4 2020 13F
Filed Feb 16, 2021
|
28 | $2.8B |
|
Q3 2020 13F
Filed Nov 16, 2020
|
35 | $1.9B |
29 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SPY P SPDR S&P 500 ETF TR | $839.1M | 29.81% |
| 2 | ZBH ZIMMER BIOMET HOLDINGS INC | $254.7M | 9.05% |
| 3 | BAX BAXTER INTL INC | $196.8M | 6.99% |
| 4 | HUM HUMANA INC | $191.8M | 6.81% |
| 5 | PFE C PFIZER INC | $172.3M | 6.12% |
| 6 | XBI P SPDR SER TR | $162.2M | 5.76% |
| 7 | CVS CVS HEALTH CORP | $152.4M | 5.42% |
| 8 | GMED GLOBUS MED INC | $91.5M | 3.25% |
| 9 | PTCT PTC THERAPEUTICS INC | $76.4M | 2.72% |
| 10 | CI THE CIGNA GROUP | $65.8M | 2.34% |
| 11 | VTRS VIATRIS INC | $65.3M | 2.32% |
| 12 | PFE PFIZER INC | $63.4M | 2.25% |
| 13 | QGEN QIAGEN NV | $56.2M | 2.0% |
| 14 | ASND ASCENDIS PHARMA A/S | $54.6M | 1.94% |
| 15 | SRPT SAREPTA THERAPEUTICS INC | $51.1M | 1.81% |
| 16 | BKD BROOKDALE SR LIVING INC | $39.1M | 1.39% |
| 17 | GSK C GSK PLC | $38.7M | 1.38% |
| 18 | BMRN BIOMARIN PHARMACEUTICAL INC | $35.3M | 1.26% |
| 19 | CON CONCENTRA GROUP HOLDINGS PAR | $34.7M | 1.23% |
| 20 | EVH EVOLENT HEALTH INC | $28.4M | 1.01% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.